Oxaliplatin Analogues with Carboxy Derivatives of Boldine with Enhanced Antioxidant Activity
A new oxaliplatin analog [Pt(dach)(L5)] (1) was synthesized and characterized as a continuation of a study of the previously reported [Pt(dach)(L6)] (2), where dach = (1R,2R)-diaminocyclohexane, L5 = 3-carboxyboldine, and L6 = 3-carboxypredicentrine. Compounds 1 and 2 exhibited a substantially enhan...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Bioinorganic Chemistry and Applications |
| Online Access: | http://dx.doi.org/10.1155/2015/920143 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562105001181184 |
|---|---|
| author | Marco Mellado Carlos Jara David Astudillo Joan Villena Patricio G. Reveco Franz A. Thomet |
| author_facet | Marco Mellado Carlos Jara David Astudillo Joan Villena Patricio G. Reveco Franz A. Thomet |
| author_sort | Marco Mellado |
| collection | DOAJ |
| description | A new oxaliplatin analog [Pt(dach)(L5)] (1) was synthesized and characterized as a continuation of a study of the previously reported [Pt(dach)(L6)] (2), where dach = (1R,2R)-diaminocyclohexane, L5 = 3-carboxyboldine, and L6 = 3-carboxypredicentrine. Compounds 1 and 2 exhibited a substantially enhanced antioxidant activity compared to oxaliplatin (130 and 30 times for 1 and 13 and 4 times for 2 using the DPPH and FRAP assays, resp.). In addition, 1 and 2 exhibited cytotoxic activity in the same range as oxaliplatin toward the two human tumor cell lines (MCF-7 and HT-29) studied and two to four times lower activity in the human colon nontumor cell line (CCD-841). Preadministration of L5 or L6 to the colon tumor (HT-29) and the colon nontumor (CCD-841) cell lines prior to oxaliplatin addition increased the viability of the nontumor cell line to a greater extent than that of the tumor cell line. |
| format | Article |
| id | doaj-art-38027ebbb9fd44bfba87a423ab446882 |
| institution | Kabale University |
| issn | 1565-3633 1687-479X |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Bioinorganic Chemistry and Applications |
| spelling | doaj-art-38027ebbb9fd44bfba87a423ab4468822025-02-03T01:23:25ZengWileyBioinorganic Chemistry and Applications1565-36331687-479X2015-01-01201510.1155/2015/920143920143Oxaliplatin Analogues with Carboxy Derivatives of Boldine with Enhanced Antioxidant ActivityMarco Mellado0Carlos Jara1David Astudillo2Joan Villena3Patricio G. Reveco4Franz A. Thomet5Departamento de Química, Universidad Técnica Federico Santa María, Avenida España 1680, 2390123 Valparaíso, ChileCentro de Investigaciones Biomédicas (CIB), Escuela de Medicina, Universidad de Valparaiso, Avenida Hontaneda 2664, 2340000 Valparaíso, ChileLaboratorio de Investigación-Estrés Oxidativo, Escuela de Medicina, Universidad de Valparaiso, Avenida Brasil 1560, 2340000 Valparaíso, ChileLaboratorio de Investigación-Estrés Oxidativo, Escuela de Medicina, Universidad de Valparaiso, Avenida Brasil 1560, 2340000 Valparaíso, ChileDepartamento de Química, Universidad Técnica Federico Santa María, Avenida España 1680, 2390123 Valparaíso, ChileDepartamento de Química, Universidad Técnica Federico Santa María, Avenida España 1680, 2390123 Valparaíso, ChileA new oxaliplatin analog [Pt(dach)(L5)] (1) was synthesized and characterized as a continuation of a study of the previously reported [Pt(dach)(L6)] (2), where dach = (1R,2R)-diaminocyclohexane, L5 = 3-carboxyboldine, and L6 = 3-carboxypredicentrine. Compounds 1 and 2 exhibited a substantially enhanced antioxidant activity compared to oxaliplatin (130 and 30 times for 1 and 13 and 4 times for 2 using the DPPH and FRAP assays, resp.). In addition, 1 and 2 exhibited cytotoxic activity in the same range as oxaliplatin toward the two human tumor cell lines (MCF-7 and HT-29) studied and two to four times lower activity in the human colon nontumor cell line (CCD-841). Preadministration of L5 or L6 to the colon tumor (HT-29) and the colon nontumor (CCD-841) cell lines prior to oxaliplatin addition increased the viability of the nontumor cell line to a greater extent than that of the tumor cell line.http://dx.doi.org/10.1155/2015/920143 |
| spellingShingle | Marco Mellado Carlos Jara David Astudillo Joan Villena Patricio G. Reveco Franz A. Thomet Oxaliplatin Analogues with Carboxy Derivatives of Boldine with Enhanced Antioxidant Activity Bioinorganic Chemistry and Applications |
| title | Oxaliplatin Analogues with Carboxy Derivatives of Boldine with Enhanced Antioxidant Activity |
| title_full | Oxaliplatin Analogues with Carboxy Derivatives of Boldine with Enhanced Antioxidant Activity |
| title_fullStr | Oxaliplatin Analogues with Carboxy Derivatives of Boldine with Enhanced Antioxidant Activity |
| title_full_unstemmed | Oxaliplatin Analogues with Carboxy Derivatives of Boldine with Enhanced Antioxidant Activity |
| title_short | Oxaliplatin Analogues with Carboxy Derivatives of Boldine with Enhanced Antioxidant Activity |
| title_sort | oxaliplatin analogues with carboxy derivatives of boldine with enhanced antioxidant activity |
| url | http://dx.doi.org/10.1155/2015/920143 |
| work_keys_str_mv | AT marcomellado oxaliplatinanalogueswithcarboxyderivativesofboldinewithenhancedantioxidantactivity AT carlosjara oxaliplatinanalogueswithcarboxyderivativesofboldinewithenhancedantioxidantactivity AT davidastudillo oxaliplatinanalogueswithcarboxyderivativesofboldinewithenhancedantioxidantactivity AT joanvillena oxaliplatinanalogueswithcarboxyderivativesofboldinewithenhancedantioxidantactivity AT patriciogreveco oxaliplatinanalogueswithcarboxyderivativesofboldinewithenhancedantioxidantactivity AT franzathomet oxaliplatinanalogueswithcarboxyderivativesofboldinewithenhancedantioxidantactivity |